Top Markets
Coin of the day
Seaport Therapeutics, Inc. Common Stock Seaport Therapeutics, Inc. Common Stock

Seaport Therapeutics, Inc. Common Stock

SPTX
Rangering i aksjer #8294
Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise... Seaport Therapeutics, Inc. is a developing biopharmaceutical enterprise currently undergoing clinical trials, focused on creating groundbreaking treatments for neuropsychiatric conditions. The company is primarily engaged in tackling disorders like depression and anxiety, utilizing its unique Glyph technology. This exclusive platform is engineered to allow for oral administration of drugs, circumventing initial metabolic processing in the liver, and thereby reducing the risk of liver enzyme elevations, hepatotoxicity, and other potential adverse reactions. Every therapeutic agent in their pipeline incorporates this advanced platform, with all research and development efforts exclusively dedicated to neuropsychiatric applications. Founded in 2024 and situated in Boston, Massachusetts, the company connects with medical professionals and influential experts across the healthcare and neuropsychiatric sectors.
Aksjekurs
$24.37
Markedsverdi
$1.30B
Endring (1 dag)
-7.16%
Endring (1 år)
-
Land
US
Handel Seaport Therapeutics, Inc. Common Stock (SPTX)

Kategori

Inntekter for Seaport Therapeutics, Inc. Common Stock (SPTX)
Inntekter i Aug 2026 TTM: 0
Ifølge de nyeste økonomiske rapportene til Seaport Therapeutics, Inc. Common Stock er selskapets nåværende inntekter (TTM) 0. I 2026 hadde selskapet inntekter på 0 lik inntektene i 2026, som var 0. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Seaport Therapeutics, Inc. Common Stock fra 2026 til 2026
Inntekter ved slutten av hvert år
År Inntekter Endre
Ikke nok data for de angitte datoene.
Inntekter for lignende selskaper eller konkurrenter
Selskap Inntekter Forskjell i inntekter Land
$12.62B -
US
$6.02B -
NL
$15.74B -
AU
$2.23B -
US
- -
CH